- Home
- NRXP vs ALGS Comparison
NRXP vs ALGS Comparison
Compare NRXP & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRXP | ALGS |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.5M | 57.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NRXP | ALGS |
|---|---|---|
| Price | $2.07 | $13.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $30.50 | ★ $60.00 |
| AVG Volume (30 Days) | ★ 461.9K | 81.5K |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $242,000.00 | ★ $2,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $643.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.17 | $3.76 |
| 52 Week High | $6.01 | $46.80 |
Technical Indicators
Market Signals| Indicator | NRXP | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 37.62 | 80.94 |
| Support Level | $2.22 | $9.10 |
| Resistance Level | $2.39 | $10.45 |
| Average True Range (ATR) | 0.15 | 0.75 |
| MACD | 0.01 | 0.38 |
| Stochastic Oscillator | 4.26 | 92.29 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.